The NIH is "a victim, not a culprit, and it urgently needs our collective help," they write. "This is a time for concern and action, not despair. Biomedical research has found itself in seemingly dire straits before, yet recouped rapidly when Congress learned that the health sciences were adversely affected by budgetary shortfalls."
In the editorial (full text below), Bishop and Varmus lay out their argument.
Bishop and Varmus shared the Nobel Prize for Physiology or Medicine in 1989, for their 1976 discovery of proto-oncogenes, normal genes that they showed have the potential to convert to cancer genes. The discovery transformed the way that scientists look at cancer and has led to new strategies for detection and treatment of the disease.
EDITORIAL IN SCIENCE, APRIL 28, 2006
(available on-line at http://www.
J. Michael Bishop, MD, Chancellor and Professor at the University of California, San Francisco and member of the Joint Steering Committee for Public Policy and the NIH Director's Advisory Council.
Harold Varmus, MD, President of the Memorial Sloan-Kettering Cancer Center, Chair of the Joint Steering Committee for Public Policy, and former director of NIH.
RE-AIM BLAME FOR NIH'S HARD TIMES
ANXIETY AND ANGER ARE RIFE AMONG THE BIOMEDICAL RESEARCH COMMUNITY OVER THE dwindling fortunes of the National Institutes of Health (NIH). The anxiety is justified: Success rates for grant applications have fallen, on average, from over 30% in 2003 to under 20% (and to even less at some Institutes), and the Bush administration's budget projections imply further declines. But the anger is another matter: Much of it is mistakenly directed at NIH itself and threatens to undermine the credibility of the agency with both its federal patrons and its public constituencies.
Between 1999 and 2003, NIH enjoyed extraordinary largesse as Congress and two successive administrations doubled its budget to about $27 billion. During this period, as expected, NIH awarded more multiyear grants, committing itself to increasing fiscal obligations in the ensuing years. At the same time, the average grant size grew beyond the rate of inflation and the number of applications also rose significantly.
After such expansion, a gradual decline toward more customary increases is required to ensure that substantial uncommitted funds are available for new grants. But the hoped-for "soft landing" did not occur. Most federal budgets, including NIH's, have flattened in the service of larger budgetary agendas, such as tax cuts and financing the war in Iraq. Congress has turned a skeptical eye on NIH, demanding to know at an unrealistically early stage what exceptional benefits the doubling has brought to those suffering from diseases and asking why NIH cannot prosper with its doubled budget. Now, facing its third consecutive year of sub-inflationary increases, NIH is likely to have 11% less spending power in 2007 than it did in 2004.
Rather than galvanizing political action to restore at least inflationary budgetary increases, these developments have precipitated an irrational response from some members of our research community. They have begun to blame the agency itself, accusing the NIH administration of mismanagement and ill-conceived adventures.
The favorite whipping boy is the recently developed NIH Roadmap. The contents of the Roadmap were shaped a few years ago by extensive consultations with extramural scientists, not invented unilaterally by the NIH leadership, and represent a response to converging forces, including demands from Congress--and from diverse physicians, disease-research advocates, and scientists--for a greater sense of mission, more risk-taking, and expanded interdisciplinary research. In its first couple of years, the Roadmap has launched laudable programs, supported mainly by highly competitive awards to individual investigators, to encourage creative but high-risk research (the Pioneer Awards); new approaches to biomedical computing, structural biology, nanomedicine, and chemical biology; and a reconfiguring of the infrastructure for clinical research.
Despite its high ambitions, the Roadmap has required no more than a modest 1.2% of the NIH budget. "Shelving" the Roadmap, as called for by one recent commentary,* would not heal NIH's financial maladies. But it just might persuade Congress and other potential critics that members of the biomedical research community are hopelessly inured to change and less concerned about the commonweal than the professional well-being of scientists.
What then is to be done? First, stop blaming NIH--it is a victim, not a culprit, and it urgently needs our collective help. Second, redirect the hue and cry to Congress and the White House. Professional societies and disease-advocate groups have taken up the cause, but investigators in the trenches have been singularly silent. And third, support NIH in its efforts to manage resources prudently: Understand the nature of its difficulty and the rationale for restricting the size of awarded grants; encourage favored treatment of applications from scientists seeking their first awards; and accept opportunities to provide advice by serving on NIH's advisory and review panels.
This is a time for concern and action, not despair. Biomedical research has found itself in seemingly dire straits before, yet recouped rapidly when Congress learned that the health sciences were adversely affected by budgetary shortfalls.† NIH still has potent allies in Congress. The public enthusiastically supports health research and recognizes that modern science is making rapid progress against feared diseases. Scientists should reinforce those alliances by making common cause with the leadership of NIH, rather than unjustly undermining its credibility.